NOV 11·Zacks CommentaryMed
UG Q3 Profit Falls Y/Y on Weak Cosmetics Sales, Stock Declines 10%
United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.
UNITED GUARDIAN INC
No enriched coverage for $UG in the last 7 days.
No SEC Form 4 filings for $UG in the last 30 days.
United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.
FONR leverages hybrid MRI tech and a strong balance sheet to navigate industry headwinds, though rising costs and regulatory risks tied to claim collections remain key challenges.
United-Guardian's Q2 earnings fall on weak cosmetic sales, partly offset by gains in pharmaceuticals and medical lubricants, with recovery hopes ahead.